Geographic Atrophy Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Geographic Atrophy pipeline constitutes 23+ key companies continuously working towards developing 25+ Geographic Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Geographic Atrophy Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Geographic Atrophy Market.

The Geographic Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Geographic Atrophy Pipeline Report: https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav
• Companies across the globe are diligently working toward developing novel Geographic Atrophy treatment therapies with a considerable amount of success over the years.
• Geographic Atrophy companies working in the treatment market are Complement Therapeutics, Apellis Pharmaceuticals, Nanoscope Therapeutics, ONL Therapeutics, NGM Biopharmaceuticals, Annexon, Genentech, Belite Bio, Inc, Aviceda Therapeutics, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Novartis, Perceive Biotherapeutics, Inc., Genentech, Inc., NGM Biopharmaceuticals, Inc, Annexon, Inc., and others, are developing therapies for the Geographic Atrophy treatment
• Emerging Geographic Atrophy therapies in the different phases of clinical trials are- CTx001, APL-2006, MCO 020, ONL 1204, NGM621, ANX 007, OpRegen, Tinlarebant, AVD-104, Zimura (avacincaptad pegol), ALK-001, Risuteganib, Elamipretide, PPY988, VOY-101, OpRegen, NGM621, ANX007, and others are expected to have a significant impact on the Geographic Atrophy market in the coming years.
• In September 2026, Ocugen, Inc. announced that the first patient has been dosed in the global Phase III registrational trial of OCU410 (AAV5-hRORA), an investigational modifier gene therapy candidate for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). The company also highlighted the recent FDA Regenerative Medicine Advanced Therapy (RMAT) designation granted to OCU410, which could support an accelerated development and regulatory review pathway. The initiation of the Phase III study marks a significant clinical development milestone for Ocugen's OCU410 program as the company advances its gene therapy approach for patients with GA.
• In July 2026, Real-world data presented at the American Society of Retina Specialists (ASRS) 2026 annual meeting in Montreal indicated that pegcetacoplan (Syfovre; Apellis Pharmaceuticals) may slow photoreceptor and retinal pigment epithelium (RPE) loss associated with geographic atrophy (GA), with a more pronounced treatment effect observed in eyes with concurrent neovascular age-related macular degeneration (nAMD). Although pegcetacoplan demonstrated a reduction in GA progression in two Phase III trials, those studies excluded patients who had nAMD alongside GA at baseline. Addressing this evidence gap, Hasenin Al-khersan, MD, of Retina Group of Florida, presented real-world clinical data evaluating pegcetacoplan in patients with this commonly encountered combination of conditions.
• In January 2026, The US Food and Drug Administration (FDA) has awarded Fast Track Designation to Complement Therapeutics' lead gene therapy candidate, CTx001, for the treatment of geographic atrophy (GA) associated with age-related macular degeneration (AMD). Earlier, in October 2025, the FDA cleared the company's Investigational New Drug (IND) application for CTx001, enabling the initiation of the Phase 1/2 Opti-GAIN study.
• In October 2025, Astellas Pharma Inc. announced the initial findings from the open-label extension phase of the Phase 3 GATHER2 trial, showing that monthly treatment with IZERVAY in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) continued to slow GA lesion progression for up to 3.5 years. The data also highlighted that earlier treatment initiation provided greater preservation of retinal tissue. IZERVAY demonstrated a favorable safety profile, with no reported cases of retinal vasculitis or occlusive vasculitis. These results, supporting the cumulative long-term benefit of IZERVAY, were presented during Retina Subspeciality Day at the American Academy of Ophthalmology 2025 Annual Meeting in Orlando.

Geographic Atrophy Overview
Geographic Atrophy (GA), alternatively termed atrophic age-related macular degeneration (AMD) or advanced Dry AMD, represents an advanced stage of age-related macular degeneration. It involves a gradual and permanent deterioration of the retina (involving photoreceptors, retinal pigment epithelium, choriocapillaris), resulting in a gradual decline in visual capabilities. GA is a persistent condition leading to progressive visual function impairment over time.

Get a Free Sample PDF Report to know more about Geographic Atrophy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Emerging Geographic Atrophy Drugs Under Different Phases of Clinical Development Include:
• CTx001: Complement Therapeutics
• APL-2006: Apellis Pharmaceuticals
• MCO 020: Nanoscope Therapeutics
• ONL 1204: ONL Therapeutics
• NGM621: NGM Biopharmaceuticals
• ANX 007: Annexon
• OpRegen: Genentech
• Tinlarebant: Belite Bio, Inc
• AVD-104: Aviceda Therapeutics
• Zimura (avacincaptad pegol): Iveric Bio
• ALK-001: Alkeus Pharmaceuticals
• Risuteganib: Allegro Ophthalmics
• Elamipretide: Stealth BioTherapeutics
• PPY988: Novartis
• VOY-101: Perceive Biotherapeutics, Inc.
• OpRegen: Genentech, Inc.
• NGM621: NGM Biopharmaceuticals, Inc
• ANX007: Annexon, Inc.

Geographic Atrophy Route of Administration
Geographic Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.

Geographic Atrophy Molecule Type
Geographic Atrophy Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Geographic Atrophy Pipeline Therapeutics Assessment
• Geographic Atrophy Assessment by Product Type
• Geographic Atrophy By Stage and Product Type
• Geographic Atrophy Assessment by Route of Administration
• Geographic Atrophy By Stage and Route of Administration
• Geographic Atrophy Assessment by Molecule Type
• Geographic Atrophy by Stage and Molecule Type

DelveInsight's Geographic Atrophy Report covers around 25+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Geographic Atrophy product details are provided in the report. Download the Geographic Atrophy pipeline report to learn more about the emerging Geographic Atrophy therapies
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key companies in the Geographic Atrophy Therapeutics Market include:
Key companies developing therapies for Geographic Atrophy are - Annexon, Inc., Regenerative Patch Technologies, LLC, Apellis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Astellas Pharma Inc, Aviceda Therapeutics, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Novartis, Perceive Biotherapeutics, Inc., Genentech, Inc., NGM Biopharmaceuticals, Inc, Gyroscope Therapeutics Limited, and others.

Geographic Atrophy Pipeline Analysis:
The Geographic Atrophy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Geographic Atrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Geographic Atrophy Treatment.
• Geographic Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Geographic Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Geographic Atrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Geographic Atrophy drugs and therapies
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Geographic Atrophy Pipeline Market Drivers
• Growing disease burden: The increasing prevalence of age-related macular degeneration (AMD), particularly among the aging population, is expected to drive demand for emerging Geographic Atrophy (GA) therapies.
• Unmet treatment needs: GA can cause progressive and irreversible vision loss, while treatment options remain limited, creating significant opportunities for novel therapies that can slow disease progression.
• Advancement in complement-targeted therapies: Increasing understanding of the complement pathway has accelerated the development of complement inhibitors and other targeted approaches designed to delay GA progression.
• Expanding clinical pipeline: Multiple investigational therapies, including complement modulators, gene therapies, and other novel approaches, are expanding the GA treatment landscape and supporting market growth.
• Rising investment in ophthalmology: Increased R&D investment by pharmaceutical and biotechnology companies is encouraging the development of disease-modifying treatments and innovative delivery technologies for GA.

Geographic Atrophy Pipeline Market Barriers
• Limited vision restoration: Most emerging therapies aim to slow GA progression rather than restore vision already lost, which may limit their perceived value among patients and physicians.
• Safety concerns: Targeting the complement system can potentially increase the risk of ocular or systemic adverse events, creating challenges for clinical development and long-term treatment.
• Frequent treatment requirements: Some therapeutic approaches require repeated intravitreal administration, which can increase the treatment burden for elderly patients and healthcare providers.
• High treatment costs: The potentially high cost of novel GA therapies, particularly biologics and advanced therapies, may create reimbursement and accessibility challenges.
• Complex disease biology: GA has a multifactorial pathophysiology, and differences in disease progression among patients can make clinical-trial design, patient selection, and demonstration of meaningful treatment benefits challenging.

Scope of Geographic Atrophy Pipeline Drug Insight
• Coverage: Global
• Key Geographic Atrophy Companies: Complement Therapeutics, Apellis Pharmaceuticals, Nanoscope Therapeutics, ONL Therapeutics, NGM Biopharmaceuticals, Annexon, Genentech, Belite Bio, Inc, Aviceda Therapeutics, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Novartis, Perceive Biotherapeutics, Inc., Genentech, Inc., NGM Biopharmaceuticals, Inc, Annexon, Inc., and others
• Key Geographic Atrophy Therapies: CTx001, APL-2006, MCO 020, ONL 1204, NGM621, ANX 007, OpRegen, Tinlarebant, AVD-104, Zimura (avacincaptad pegol), ALK-001, Risuteganib, Elamipretide, PPY988, VOY-101, OpRegen, NGM621, ANX007, and others
• Geographic Atrophy Therapeutic Assessment: Geographic Atrophy current marketed and Geographic Atrophy emerging therapies
• Geographic Atrophy Market Dynamics: Geographic Atrophy market drivers and Geographic Atrophy market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.